The world's largest publicly-traded coal producer is having its geopolitical moment. Japan announced it would increase coal plant operating rates to offset LNG procurement risk from the Middle East — thermal coal prices jumped over 21% in March alone, with one analyst flagging a potential 46% price spike if the Iran supply bloc deteriorates further. Peabody's Centurion longwall mine started two months ahead of schedule. The stock has moved from a 52-week low of $9.61 to a recent high of $41.14 — nearly a 4x move — yet BTU still trades at just 6x 2026 earnings with zero net debt. The coal-for-AI-power-demand narrative (Trump Pentagon coal orders) adds a longer-horizon thesis layered on top.

The downstream refiner that nobody talked about for three years is suddenly everywhere. DK posted an adjusted EPS of $2.31 vs. analyst consensus of -$0.07 — a 3,400% positive surprise. The catalyst: a $150M benefit from updated Small Refinery Exemption accounting, elevated refining margins, and strategic cost cuts. The stock is up 186.8% over the trailing year. Multiple analyst upgrades: Mizuho PT $54, Raymond James PT $54 (Outperform). Geopolitical oil price elevation adds further refining economics fuel. Risk: high leverage (D/E 11.54) and insider selling via pre-arranged 10b5-1 plans — but scheduled, not reactive.

The world's largest methanol producer is catching a double tailwind: Middle East supply disruptions have reduced Iranian exports significantly, driving Chinese prices above $300/tonne and European spot near $400/tonne. Jefferies raised PT to $60, UBS to $60, BMO Capital Markets to $70 — all citing supply constraints persisting for months, with Methanex's 9M tonne 2026 production guidance locking in volume at elevated prices. The OCI Global acquisition is now fully integrated. FCF is being directed to debt paydown. The first UK commercial biomethanol bunkering service adds an ESG institutional angle.

The laser company at the center of NVIDIA's AI infrastructure buildout. AAOI secured a $200M order for 1.6T transceivers — possibly from Oracle — and management guided full-year 2026 revenue to potentially exceed $1 billion (from $456M in 2025). Q4 data center revenue hit $74.9M, up 69% year-over-year. The 800G transceiver ramp begins Q2 2026 and could unlock $25M+ in a single quarter. AAOI is building a 210,000 sq ft Texas facility and scaling toward 500,000 units/month. Rosenblatt raised PT to $140. The risk: $250M ATM equity program creates dilution overhang, and operating expenses remain elevated at $50-57M/quarter while the ramp completes.

Fabrinet is the quiet industrial partner behind the AI photonics revolution — providing precision optical and electro-mechanical manufacturing to OEMs that can't build their own. FN stock has appreciated roughly 171% since April 2025 analyst coverage. Fiscal 2026 EPS consensus is $13.58/share (revised up), with fiscal 2027 at $16.18 (up 4.9% in 60 days). Unlike AAOI, Fabrinet carries no dilution overhang and offers more stable, diversified revenue across telecom and data center verticals. The Amazon warrant deal strengthens its hyperscaler supply chain position. More stable/less volatile than AAOI — Zacks Rank #2 (Buy).

The photomask manufacturer is semiconductor's most underappreciated infrastructure play. PLAB printed Q1 FY2026 revenue of $225M — 6.1% YoY beat — with record high-end IC revenue of $71M (+19% YoY). Gross margin hit 35% and operating cash flow of $97M was the second highest in company history. Craig-Hallum raised PT to $48 (Buy). Fiscal 2026 CapEx guidance of $330M signals aggressive investment to capture the next wave of advanced node demand. Limited sell-side coverage means institutional accumulation is happening before the broader market prices it in. Stock at ~$42.52 with Q2 guidance of $212-$220M revenue.

WeRide reported record FY2025 revenue of $97.9M — up 89.6% year-over-year — with a 30.2% gross margin and narrowing operating loss. The global AV fleet reached 1,125 robotaxis; 2026 target is 2,600 vehicles. This week: Slovakia launch (4th European market), WeChat Tencent integration in Guangzhou, and a binding agreement to deliver 2,000 Robotaxi GXR vehicles powered by NVIDIA DRIVE Hyperion. The GXR's HPC 3.0 cuts autonomous suite cost 50% and total cost of ownership 84%. A $100M share repurchase program was authorized. Risk: US geopolitical scrutiny of Chinese-founded AV companies is a persistent overhang.

The only pure-play commercial lunar infrastructure company won its fifth NASA mission: IM-5, worth $180.4M under the Commercial Lunar Payload Services program — the stock surged 19.8% on the announcement. The 2026 revenue guide is $900M-$1B — nearly 5x the $210M printed in 2025 — anchored by a $943M backlog and the $800M Lanteris acquisition. Stifel PT at $22. The volatility is severe; LUNR swung +20% to -12% in the same week after a Q4 revenue miss. This is speculative infrastructure with a 10-year NASA contract (through 2034) as the spine.

The neutral-atom quantum computing company delivered the UK's only operational 100-physical-qubit quantum computing system to the National Quantum Computing Centre in Oxford — a live deployment, not a demo. The company was selected for $3.9M in ARPA-E funding. Stock is down ~38% from its October 2025 high of $27.50, trading ~$9-10, creating a potential entry window ahead of the ARPA-E Summit presentation on April 7 and an upcoming Analyst Day. The UK's $2B quantum plan is a direct sector catalyst alongside IonQ and IBM quantum investments.

ANKTIVA is becoming a multi-jurisdiction commercial product. ImmunityBio reported $113M in full-year 2025 net product revenue — a 668% year-over-year increase. The company resubmitted a supplemental BLA to the FDA in March 2026 for papillary-only bladder cancer, and the 2026 NCCN guidelines now include ANKTIVA plus BCG as Category 2A. Stock up ~347% in 90 days. EU conditional marketing authorization is live; a Saudi Arabia commercial partnership (MENA expansion) is active. QUILT-2.005 enrollment is complete with a supplemental BLA on track for Q4 2026. All 5 covering analysts rate Strong Buy; avg PT $14.40 vs. ~$8 current price. Risk: FDA warning about promotional claims requires monitoring.

Merck's acquisition of Terns Pharmaceuticals lit the fuse. The deal validated the CML drug market exactly when Enliven was announcing strong Phase 1b data — ELVN-001 showed cumulative MMR of 69% by 24 weeks in the 60/120mg cohorts, a class-leading result. The stock surged 15% on March 25 and an additional 14% on March 26. A pivotal Phase 3 trial is planned to start in 2026. Cash of $462.6M funds operations into H1 2029 — no near-term dilution risk. New CEO Rick Fair brings experience launching $23B in pharmaceutical products. This is a clinical-stage name with a de-risked development path and M&A validation from one of the world's largest pharma companies.

The most-appeared ticker of the week had one of the more unusual catalysts in recent memory: TSA staffing disruptions caused by DHS funding gridlock turned airport security lines into a nightmare — and suddenly driving looks appealing again. Avis is running a 25% spring discount to capture exactly this moment. The stock surged 13% on Thursday alone, closing at $143+ from an $80s base. A potential short squeeze adds momentum (beta 2.32, heavily shorted). Deutsche Bank maintained Buy while cutting PT from $148 to $128. Risk: -$995M FY2025 net loss, $8.66B long-term debt, negative profit margin. The Waymo fleet management partnership (Dallas) adds a long-horizon AV angle. An at-the-market equity offering announced March 27 creates near-term dilution.

Japan's dominant mobile payment platform debuted on Nasdaq on March 12, 2026 — priced at $16 (below the $17-$20 range due to Middle East volatility), opening at $19 and climbing to $24.89. PayPay holds 64% of Japan's QR payment market with 72 million registered users, and the Japanese government's 80% cashless target creates structural runway. Macquarie initiated with Outperform ($22.90 PT). Cathie Wood's ARK bought 275K shares on day one. Backed by SoftBank, Qatar Investment Authority, Visa, and Abu Dhabi Investment Authority. Risk: trading at a premium to fair value models, newly-public IPO volatility.

Braze appeared on the top gainers list in the days before Q4 FY2026 earnings — then dropped 18% after reporting. Q4 results: $205.2M revenue (+27.9% YoY), the strongest new customer addition quarter in three years (106 sequential adds), and AI-powered features delivering a 12% uplift in app downloads for customers. NRR at 108%. Remaining performance obligations of $891.4M provide visibility. Operating loss narrowed 31% YoY. The post-earnings drawdown creates a re-entry question for believers in the AI-powered customer engagement thesis. Top-gainer appearances reflect pre-earnings momentum; the post-earnings price action is the current narrative.

The Jack Daniel's maker showing up on top gainers is itself the signal worth reading. BF-B's Q3 FY2026 results showed whiskey net sales growing 2% organic — the first increase in over two years — driven by Jack Daniel's Tennessee Blackberry innovation. Stock near multi-year lows (~$23-25) after declining 63% over three years. A 42-consecutive-year dividend streak and $400M share buyback are the floor arguments. The bear case is well-documented: tariff risk on EU whiskey exports, Gen Z alcohol decline, declining domestic volume, and Bernstein downgrade. FCF payout ratio dangerously close to 1.0x. Top-gainer appearances reflect dividend yield chasers and deep-value snapbacks — not trend momentum.